Author

Jordan T.F. Young

AstraZeneca (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1

Frequent Co-Authors

Alejandro Álvarez-QuilóniD· 3 shared Julian Bowlan· 3 shared Nancy LaterreuriD· 3 shared Artur VelosoiD· 2 shared Chris Fiore· 2 shared Daniel DurocheriD· 2 shared Li Li· 2 shared Mark E. OrcholskiiD· 2 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Alejandro Álvarez-QuilónORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

CRISPR-enabled genetic screens identify synthetic lethal targets across frequently altered cancer drivers

Jessica Desjardins, Julian Bowlan, Cynthia Bernier, Srishti Jain, Théo Goullet de Rugy, David Gallo, Mark E. Orcholski, Nancy Laterreur, Abira Rajah, Joshua Miller, Jennifer A. Lafontaine, Vivek Bhaskaran, Li Li, Alexanda K. Ling, Jesse H. Leblanc, , Jordan T.F. Young

This study identifies synthetic lethal interactions between cancer drivers and tractable targets using CRISPR screens and cancer dependency data, offering new drug targets for therapy.

bioRxiv · Jan 25, 2026 · PreprintCancer Biology

Anticipating on-target resistance to WRN inhibitors in microsatellite unstable cancers

Mark E. Orcholski, Nancy Laterreur, Wardah Masud, Shamika Shenoy, Vincent Chapdelaine, Julian Bowlan, Amisha Minju-OP, Júlia-Jié Cabré-Romans, Tanja Sack, Chris Fiore, Jordan T.F. Young, Alejandro Álvarez-Quilón, Raquel Cuella-Martin

This study identifies on-target resistance mechanisms to WRN inhibitors in MSI cancers using functional genomics and shows how to improve therapeutic durability through drug selection and combination strategies.

bioRxiv · Jan 24, 2026 · PreprintCancer Biology

A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma

Isabel Soria‐Bretones, Matias Casás‐Selves, Elliot Goodfellow, Li Li, Cathy Caron, Ariya Shiwram, Hye‐Yeon Kim, Danielle Henry, Nancy Laterreur, Julian Bowlan, Alejandro Álvarez-Quilón, Frédéric Vallée, Artur Veloso, Jordan T.F. Young, Marc L. Hyer, , Michal Zimmermann

This study shows neuroblastoma cells are hypersensitive to PLK4 inhibitor RP-1664 due to dual mechanisms of centriole loss and amplification, leading to cell death.

bioRxiv · Feb 15, 2025 · PreprintCancer Biology

Profound synthetic lethality between SMARCAL1 and FANCM

Sumin Feng, Kaiwen Liu, Jinfeng Shang, Lisa Hoeg, Graziana Pastore, William E. Yang, Sabrina Roy, Guillermo Sastre-Moreno, Jordan T.F. Young, Wei Wu, Dongyi Xu, Daniel Durocher

The paper identifies a synthetic lethal relationship between SMARCAL1 and FANCM, showing their combined loss causes severe genome instability due to chromosome breakage at simple repeat regions.

Molecular Cell · Nov 6, 2024Peer-reviewedMolecular Biology